FDA Says It Plans Label Changes for Concerta and Ritalin
WASHINGTON-The FDA said it plans to strengthen the warning label for Concerta, the popular long-acting version of Ritalin (methylpenidate) in response to post-marketing surveillance reports of psychiatric and cardiovascular adverse effects.
Jun 29, 2005